









Markets
/
Stocks
/
nasdaq-crsp
/

CRISPR Therapeutics AG

CRSP

51.230USD

-2.120-3.97%

Market hours （ET）Quotes delayed by 15 min

4.81BMarket Cap

LossP/E TTM



CRISPR Therapeutics AG

51.230

-2.120-3.97%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CRISPR Therapeutics AG

Currency: USD Updated: 2026-01-29

Key Insights

CRISPR Therapeutics AG's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 108 out of 393 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 81.52.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CRISPR Therapeutics AG's Score

Industry at a Glance

Industry Ranking

108 / 393

Overall Ranking

224 / 4540

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

CRISPR Therapeutics AG Highlights

StrengthsRisks

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 3014.69% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 37.31M.

Fairly Valued

The company’s latest PE is -9.63, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 79.52M shares, increasing 0.09% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 10.68K shares of this stock.

Analyst Rating

Based on 29 analysts

Buy

Current Rating

81.524

Target Price

+50.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-29

The current financial score of CRISPR Therapeutics AG is 6.29, ranking 273 out of 393 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 889.00K, representing a year-over-year increase of 47.67%, while its net profit experienced a year-over-year increase of 23.85%.

Score

Industry at a Glance

Previous score

6.29

Change



Financials

6.79

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.28

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

CRISPR Therapeutics AG's Company Valuation

Currency: USD Updated: 2026-01-29

The current valuation score of CRISPR Therapeutics AG is 6.72, ranking 234 out of 393 in the Biotechnology & Medical Research industry. Its current P/E ratio is -9.63, which is -100.00% below the recent high of 0.00 and -377.51% above the recent low of -45.96.

Score

Industry at a Glance

Previous score

6.72

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 108/393

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-29

The current earnings forecast score of CRISPR Therapeutics AG is 7.59, ranking 282 out of 393 in the Biotechnology & Medical Research industry. The average price target is 74.50, with a high of 268.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

7.59

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 29 analysts

Buy

Current Rating

81.524

Target Price

+50.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

541

Total

Median

Average

Company name

Ratings

Analysts

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

Kymera Therapeutics Inc

KYMR

...

108

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-29

The current price momentum score of CRISPR Therapeutics AG is 6.51, ranking 244 out of 393 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 59.14 and the support level at 49.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.54

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.354

Sell

RSI(14)

45.459

Neutral

STOCH(KDJ)(9,3,3)

28.728

Sell

ATR(14)

3.011

Low Volatility

CCI(14)

-89.198

Neutral

Williams %R

76.166

Sell

TRIX(12,20)

-0.040

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

54.294

Sell

MA10

54.734

Sell

MA20

55.174

Sell

MA50

54.933

Sell

MA100

58.935

Sell

MA200

53.264

Sell

Institutional Confidence

Currency: USD Updated: 2026-01-29

The current institutional shareholding score of CRISPR Therapeutics AG is 7.00, ranking 85 out of 393 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 84.90%, representing a quarter-over-quarter decrease of 5.23%. The largest institutional shareholder is Catherine Wood, holding a total of 9.79M shares, representing 10.27% of shares outstanding, with 12.75% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

9.79M

-3.89%

BlackRock Institutional Trust Company, N.A.

6.25M

+15.30%

Capital International Investors

5.65M

+0.99%

Orbis Investment Management Ltd.

4.98M

+80.21%

State Street Investment Management (US)

4.01M

+22.52%

T. Rowe Price Investment Management, Inc.

3.28M

-10.87%

UBS Financial Services, Inc.

2.28M

-11.70%

The Vanguard Group, Inc.

Star Investors

2.35M

+2.92%

Amova Asset Management Americas, Inc

2.16M

-10.38%

Geode Capital Management, L.L.C.

2.14M

+3.34%

Risk Assessment

Currency: USD Updated: 2026-01-29

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CRISPR Therapeutics AG is 5.14, ranking 55 out of 393 in the Biotechnology & Medical Research industry. The company's beta value is 1.72. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.